Literature DB >> 24638202

Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.

Muriel Stoppe1, Eva Thomä, Uwe Gerd Liebert, Eugene O Major, Karl-Titus Hoffmann, Joseph Claßen, Florian Then Bergh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24638202     DOI： 10.1007/s00415-014-7311-1

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  11 in total

1.  JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy.

Authors:  Igor J Koralnik; Christian Wüthrich; Xin Dang; Matthew Rottnek; Alejandra Gurtman; David Simpson; Susan Morgello
Journal:  Ann Neurol       Date:  2005-04       Impact factor: 10.422

Review 2.  Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.

Authors:  Per Soelberg Sørensen; Antonio Bertolotto; Gilles Edan; Gavin Giovannoni; Ralf Gold; Eva Havrdova; Ludwig Kappos; Bernd C Kieseier; Xavier Montalban; Tomas Olsson
Journal:  Mult Scler       Date:  2012-02       Impact factor: 6.312

3.  PML in a patient treated with dimethyl fumarate from a compounding pharmacy.

Authors:  Bob W van Oosten; Joep Killestein; Frederik Barkhof; Chris H Polman; Mike P Wattjes
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

4.  Manufacturer's response to case reports of PML.

Authors:  Marianne T Sweetser; Katherine T Dawson; Carmen Bozic
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

5.  PML in a patient treated with fumaric acid.

Authors:  Ummehan Ermis; Joachim Weis; Jörg B Schulz
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

6.  Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus.

Authors:  Ryan P Moenster; R Andrew Jett
Journal:  Am J Health Syst Pharm       Date:  2012-03-15       Impact factor: 2.637

7.  Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Authors:  Ralf Gold; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Gavin Giovannoni; Krzysztof Selmaj; Carlo Tornatore; Marianne T Sweetser; Minhua Yang; Sarah I Sheikh; Katherine T Dawson
Journal:  N Engl J Med       Date:  2012-09-20       Impact factor: 91.245

8.  Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants.

Authors:  Caroline F Ryschkewitsch; Peter N Jensen; Eugene O Major
Journal:  J Clin Virol       Date:  2013-04-23       Impact factor: 3.168

Review 9.  The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Mike P Wattjes; Nancy D Richert; Joep Killestein; Marlieke de Vos; Esther Sanchez; Petur Snaebjornsson; Diego Cadavid; Frederik Barkhof
Journal:  Mult Scler       Date:  2013-11-05       Impact factor: 6.312

10.  Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons.

Authors:  Christian Wüthrich; Xin Dang; Susan Westmoreland; John McKay; Atul Maheshwari; Matthew P Anderson; Allan H Ropper; Raphael P Viscidi; Igor J Koralnik
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422
View more
  16 in total

1.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 2.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 3.  Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Authors:  Robbert-Jan Gieselbach; Annemarie H Muller-Hansma; Martijn T Wijburg; Marjolein S de Bruin-Weller; Bob W van Oosten; Dennis J Nieuwkamp; Frank E Coenjaerts; Mike P Wattjes; Jean-Luc Murk
Journal:  J Neurol       Date:  2017-05-23       Impact factor: 4.849

Review 4.  Host-Immune Interactions in JC Virus Reactivation and Development of Progressive Multifocal Leukoencephalopathy (PML).

Authors:  Amir Khalili; Michael Craigie; Martina Donadoni; Ilker Kudret Sariyer
Journal:  J Neuroimmune Pharmacol       Date:  2019-08-27       Impact factor: 4.147

Review 5.  Oral Therapies for Multiple Sclerosis.

Authors:  Simon Faissner; Ralf Gold
Journal:  Cold Spring Harb Perspect Med       Date:  2019-01-02       Impact factor: 6.915

6.  Lack of Major Histocompatibility Complex Class I Upregulation and Restrictive Infection by JC Virus Hamper Detection of Neurons by T Lymphocytes in the Central Nervous System.

Authors:  Christian Wüthrich; Stephanie Batson; Igor J Koralnik
Journal:  J Neuropathol Exp Neurol       Date:  2015-08       Impact factor: 3.685

7.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

Review 8.  Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors:  Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal:  Ann Neurol       Date:  2015-07-31       Impact factor: 10.422

Review 9.  Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature.

Authors:  Martijn T Wijburg; Bob W van Oosten; Jean-Luc Murk; Ouafae Karimi; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2014-10-09       Impact factor: 6.682

Review 10.  Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.

Authors:  Simon Faissner; Ralf Gold
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 6.497
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.